ArticleKorean circulation journal2012
High serum advanced glycation end-products predict coronary artery disease irrespective of arterial stiffness in diabetic patients.
Article in Korean circulation journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Modulation of circulating levels of advanced glycation end products and its impact on intima-media thickness of both common carotid arteries: CORDIOPREV randomised controlled trial.Cardiovascular diabetology · 2024Trial
- Article
- Periodontitis and implant complications in diabetes.Periodontology 2000 · 2022Review
- Glycosylated hemoglobin, but not advanced glycation end products, predicts severity of coronary artery disease in patients with or without diabetes.Metabolism open · 2020Article
- Association between IL-1beta and cardiovascular disease risk in patients with newly diagnosed, drug-naïve type 2 diabetes mellitus: a cross-sectional study.Annals of translational medicine · 2020Article
- Usability of Achilles tendon strain elastography for the diagnosis of coronary artery disease.Journal of medical ultrasonics (2001) · 2019Article
- Advanced glycation end products in isoproterenol-induced acute myocardial infarction.Medicine and pharmacy reports · 2019Article
- Article
- Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study.Diabetes care · 2017Article
- Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?The International journal of angiology : official publication of the International College of Angiology, Inc · 2017Review
- A Comparative Study on Skin and Plasma Advanced Glycation End Products and Their Associations with Arterial Stiffness.Pulse (Basel, Switzerland) · 2017Article
- Generation and characterization of monoclonal antibody against Advanced Glycation End Products in chronic kidney disease.Biochemistry and biophysics reports · 2016Article
- Arterial stiffness, fatty liver and the presence of coronary artery calcium in a large population cohort.Cardiovascular diabetology · 2013Article
- Effect of the blood HbA1c level on surgical treatment outcomes of diabetics with ankle fractures.Orthopaedic surgery · 2013Article
- Advanced Glycation End Products and Risks for Chronic Diseases: Intervening Through Lifestyle Modification.American journal of lifestyle medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAdvanced glycation end-products (AGEs) contribute to the development of atherosclerosis. We investigated whether serum AGEs are related to the presence or severity of coronary artery disease (CAD), and explored the association between serum AGEs and arterial stiffness according to diabetes status in patients suspected of having CAD. SUBJECTS AND
methodsThe measurement of serum AGEs and brachial-ankle pulse wave velocity (baPWV) were performed in 145 consecutive patients (63±9 years, 58% men) who received a coronary angiogram for evaluation of CAD.
resultsForty-four diabetics and 101 non-diabetics were classified into three subgroups based on the number of diseased vessels with obstructive CAD: 0, 1, and 2 or more vessel diseases (VDs). Serum AGEs were significantly higher in diabetics with obstructive CAD than in those without obstructive CAD (2.16±0.29 vs. 1.85±0.29 mU/mL, p=0.010) and were significantly correlated with the number of VDs only in diabetics (r=0.504, p<0.001). Serum AGEs were not significantly correlated with baPWV in diabetics or non-diabetics. In receiver operating characteristics analysis, the cut-off value of serum AGEs as a predictor of obstructive CAD was 1.98 mU/mL, with 64% sensitivity and 63% specificity in diabetics. In multiple regression analysis, serum AGEs independently predicted obstructive CAD and were associated with the number of VDs in diabetics.
conclusionSerum AGEs independently predict obstructive CAD and the severity of coronary atherosclerosis irrespective of arterial stiffness only in diabetics. Evaluation of PWV and serum AGEs together may be more effective to identify the risk of CAD in diabetic individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.